Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Achilles Therapeutics plc ACHL

Healthcare Biotechnology
Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma ... see more

Recent & Breaking News (NDAQ:ACHL)

Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

GlobeNewswire 5 days ago

Achilles Therapeutics Reports Third Quarter 2024 Financial Results

GlobeNewswire 10 days ago

Achilles Therapeutics Announces Strategic Update

GlobeNewswire September 19, 2024

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

GlobeNewswire August 14, 2024

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

GlobeNewswire May 22, 2024

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

GlobeNewswire May 17, 2024

Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire May 8, 2024

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

GlobeNewswire April 4, 2024

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

GlobeNewswire April 4, 2024

Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

GlobeNewswire February 5, 2024

Achilles Therapeutics Announces Publication of Nature Cancer 'Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction

GlobeNewswire December 18, 2023

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire November 13, 2023

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

GlobeNewswire September 22, 2023

Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

GlobeNewswire August 4, 2023

Achilles Therapeutics to Present at Upcoming Conferences

GlobeNewswire June 12, 2023

Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

GlobeNewswire May 10, 2023

Achilles Therapeutics' New Immunogenicity Prediction Application of its AI-Powered PELEUS(TM) Platform Uniquely Identifies the Most Potent T Cell Antigens

GlobeNewswire May 10, 2023

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

GlobeNewswire April 25, 2023

Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status

GlobeNewswire April 25, 2023

Achilles Therapeutics to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

GlobeNewswire April 17, 2023